Osteonectin (SPARC) prognostic value in prostate cancer
- PMID: 38199134
- DOI: 10.1016/j.prp.2023.155053
Osteonectin (SPARC) prognostic value in prostate cancer
Abstract
Background: Prostate cancer (PCa) is common malignancy among men worldwide. To date only few molecular markers are available to predict its course and outcome. SPARC is considered to be promising prognostic marker of PCa due to its involvement in various cancer processes.
Materials and methods: study was conducted on PCa surgical primary tumor samples, obtained from 84 patients. Level of SPARC mRNA expression was estimated using RT-qPCR. To identify SPARC protein (osteonectin) in prostate tissue, immunohistochemical analysis was conducted. Bioinformatical analysis was performed on UALCAN and TNMplot resources.
Results: bioinformatical analysis demonstrated that SPARC mRNA levels are decreased in PCa samples, in comparison to normal tissue. In patients with lymph node metastases its levels are 1.26 times higher; p = 4.66E-02, than in N0 category. Ex vivo study demonstrated that SPARC expression was elevated on both mRNA and protein levels in PCa patients with lymph node metastases (by 2.34 and 1.91, respectively, p < 0.05). We established higher levels of SPARC mRNA and protein in PCa patients with T3 tumors, as well as high Gleason score. Estimation of survival rates demonstrated that PCa patients with a high level of SPARC mRNA and protein have decreased overall 2-year survival.
Conclusions: SPARC protein was overexpressed on mRNA and protein levels in patients with presence of lymph node metastases and higher Gleason score of tumors. Also, both mRNA and protein upregulation were associated with worse survival rates. The current study has therefore provided further evidence that SPARC is indeed linked to the prognosis and aggressiveness of human PCa.
Keywords: MRNA; Prognosis; Prostate cancer; SPARC.
Copyright © 2024 Elsevier GmbH. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
EXPRESSION OF SPP1 AND SPARC GENES IN TUMOR TISSUE OF PATIENTS WITH BREAST CANCER.Exp Oncol. 2024 May 31;46(1):13-21. doi: 10.15407/exp-oncology.2024.01.013. Exp Oncol. 2024. PMID: 38852057
-
Prognostic Significance of SPARC Expression in Breast Cancer: A Meta-Analysis and Bioinformatics Analysis.Biomed Res Int. 2022 Feb 15;2022:8600419. doi: 10.1155/2022/8600419. eCollection 2022. Biomed Res Int. 2022. PMID: 35211625 Free PMC article. Review.
-
Comprehensive Analysis of Secreted Protein, Acidic and Rich in Cysteine in Prostate Carcinogenesis: Development of a 3D Nanostructured Bone-Like Model.J Biomed Nanotechnol. 2016 Aug;12(8):1667-78. doi: 10.1166/jbn.2016.2276. J Biomed Nanotechnol. 2016. PMID: 29342345
-
Hypermethylation of the SPARC promoter and its prognostic value for prostate cancer.Oncol Rep. 2018 Feb;39(2):659-666. doi: 10.3892/or.2017.6121. Epub 2017 Nov 29. Oncol Rep. 2018. PMID: 29207175
-
Pelvic lymph node dissection in prostate cancer.Eur Urol. 2009 Jun;55(6):1251-65. doi: 10.1016/j.eururo.2009.03.012. Epub 2009 Mar 10. Eur Urol. 2009. PMID: 19297079 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous